Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Company Contact
Address: 4464 Markham St Unit 3204
VICTORIA BC V8Z 7X8
Tel: N/A
Website: https://immunoprecise.com
IR: See website
Key People
N/A    
Business Overview
Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production and Cryopreservation Services. Its antibody products include IPA006A, IPA006B and IPA006F, which it offers to the research and industrial community. Its hybridoma licensing products include Anti-Human P38a (MAPKinase) Monoclonal Antibody Hybridoma Cell Line and Anti-Acetylated Lysine Monoclonal Antibody Hybridoma Cell Line. It offers cryopreservation storage service for the secure storage of users' valuable biological materials, including hybridoma clones, plasmid constructs and cell lines. It also offers both peptide synthesis and protein carrier conjugation services.
Financial Overview
For the three months ended 31 July 2019, Immunoprecise Antibodies Ltd revenues decreased 5% to C$2.7M. Net loss increased 83% to C$2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Amortization and depreciation increase from C$176K to C$548K (expense), Deferred Acquisition Payments increase from C$114K to C$457K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $38.83M as of Jul 31, 2019
Annual revenue (TTM): $10.77M as of Jul 31, 2019
EBITDA (TTM): -$4.12M as of Jul 31, 2019
Net annual income (TTM): -$8.53M as of Jul 31, 2019
Free cash flow (TTM): -$3.99M as of Jul 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 67,989,445 as of Jul 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization